More than Thirty Abstracts on VELCADE® and Leading Millennium: The Takeda Oncology Company Pipeline Compounds to be Presented in Oral Sessions at 53rd American Society of Hematology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced 32 abstracts, involving six molecules in the Company’s portfolio, have been accepted for oral presentation at this year’s American Society of Hematology (ASH) annual meeting to be held December 10-13, 2011 in San Diego, California. These abstracts include oral presentations for VELCADE (bortezomib) for Injection and five of the Company’s pipeline agents, including MLN9708, the first oral proteasome inhibitor being studied in patients.